Biography & Early Wealth Journey

Harvard University (Photo by Maddie Meyer/Getty Images)

Springer did his undergraduate work at the University of California, Berkeley, and his Ph.D. at Harvard. Springer is Moderna's fourth-largest shareholder and made $400 million from the company's IPO. More recently, Springer, 72, has ridden a 17,000% return in his Moderna shares, which has gained him entrance to the exclusive billionaire's club. Shares of Moderna are up 162% so far this year on news of its work on a coronavirus vaccine. The company is one of the first to start human trials on a vaccine for COVID-19. The U.S. government recently agreed to give Moderna $438 million to develop the coronavirus vaccine.

Springer saw his first big break in making millions during the dot-com bubble of 1999. He sold his first venture, LeukoSite to Millennium Pharmaceuticals for $100 million. He took $5 million of his profit from that and invested it in pre-IPO Moderna. Springs is also the founder of biotechnology companies Morphic Therapeutic and Scholar Rock.